Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pharmacokinetic interaction · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pharmacokinetic (how the body absorbs and eliminates) interaction | DRUG | - |
1. Men and women, aged 18 to 50 years. Women of non-childbearing potential may be included. 2. Body mass index in the range of 18 to 30 kg/meter squared and body weight equal to or greater than 50 kg. 3. Healthy as determined by the investigator on the basis of medical history, physical examination,...
It is a Phase 1 study evaluating how the body absorbs and eliminates a drug when a CYP2C9 inhibitor is given with a CYP2C9 substrate. The trial examined the potential drug interaction between these two agents in healthy adult subjects. Pfizer, Inc. conducted the research under NCT00369304.
The pharmacokinetic interaction study was designed to characterize how a CYP2C9 inhibitor affects the absorption and elimination of a CYP2C9 substrate. It was conducted in healthy volunteers rather than in patients with a specific disease, so it does not have a therapeutic indication. The trial is complete.
Pfizer, Inc. (ticker PFE) is the developer of the pharmacokinetic interaction study. The company sponsored the Phase 1 trial NCT00369304, which evaluated the potential drug interaction between a CYP2C9 inhibitor and a CYP2C9 substrate in healthy subjects.
The pharmacokinetic interaction study is a Phase 1 trial, and it has been completed. It was an uncontrolled, randomized study conducted in healthy volunteers aged 18 years and older. No active trials of this pharmacokinetic interaction are currently listed.
The pharmacokinetic interaction was evaluated in one completed Phase 1 trial, NCT00369304, titled Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate. The trial enrolled healthy volunteers, was randomized, and used an uncontrolled design without blinding.